All In Biotech

Drug Trial Radar · NCT07040319

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 25, 2026

Primary completion

Mar 3, 2028

Study completion Mar 3, 2028

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); AbbVie
First posted
Jun 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 16 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum.

Conditions

  • Hepatitis C

Interventions

  • Glecaprevir/pibrentasvirDrug

    100 mg glecaprevir and 40 mg pibrentasvir for a total daily dose of glecaprevir 300 mg/pibrentasvir 120 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean AUC0-24hTime frame: At weeks 3 & 6
  2. Geometric mean CmaxTime frame: At weeks 3 & 6
  3. Geometric mean C24hTime frame: At weeks 3 & 6
  4. Percentage of pregnant/ postpartum participants who experience a grade 3 or higher adverse event assessed as related to study drugTime frame: Initiation of treatment to a) completion of treatment and b) latter of 10 weeks post-partum or 20 weeks post treatment initiation
  5. Percentage of pregnant participants who experience a serious adverse event assessed as related to study drugTime frame: Initiation of treatment to a) completion of treatment and b) latter of 10 weeks post-partum or 20 weeks post treatment initiation

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • USC LA

    Los Angeles, California · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Not yet recruiting

  • University of Colorado Denver

    Aurora, Colorado · Recruiting

  • Univ. of Florida Jacksonville

    Jacksonville, Florida · Recruiting

  • Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Johns Hopkins University Baltimore

    Baltimore, Maryland · Recruiting

  • SUNY Stony Brook

    Stony Brook, New York · Recruiting

  • Bronx-Lebanon Hospital Center

    The Bronx, New York · Recruiting

  • Jacobi Medical Center

    The Bronx, New York · Not yet recruiting

  • Baylor College of Medicine//Texas Children's Hospital

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.